These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
15. Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro versus Integrilin Cost Evaluation (PRICE) Trial. PRICE Investigators Am Heart J; 2001 Mar; 141(3):402-9. PubMed ID: 11231437 [TBL] [Abstract][Full Text] [Related]
16. Long-term clinical benefits of a platelet glycoprotein IIb/IIIa receptor blocker, abciximab (ReoPro), in high-risk diabetic patients undergoing percutaneous coronary intervention. Sim DS; Jeong MH; Kim W; Rhew JY; Yum JH; Kim JH; Cho JG; Ahn YK; Park JC; Ahn BH; Kim SH; Kang JC Korean J Intern Med; 2003 Sep; 18(3):129-37. PubMed ID: 14619381 [TBL] [Abstract][Full Text] [Related]
17. Effects of platelet glycoprotein IIb/IIIa inhibition with abciximab on thrombin generation and activity during percutaneous coronary intervention. Dangas G; Marmur JD; King TE; De Leon J; Sharma SK; Vidhun R; Feldman D; Stoynov MY; Badimon JJ; Ambrose JA Am Heart J; 1999 Jul; 138(1 Pt 1):49-54. PubMed ID: 10385763 [TBL] [Abstract][Full Text] [Related]
18. Early administration of abciximab bolus in the emergency department improves angiographic outcome after primary PCI as assessed by TIMI frame count: results of the early ReoPro administration in myocardial infarction (ERAMI) trial. Gabriel HM; Oliveira JA; da Silva PC; da Costa JM; da Cunha JA Catheter Cardiovasc Interv; 2006 Aug; 68(2):218-24. PubMed ID: 16817177 [TBL] [Abstract][Full Text] [Related]
19. Comparison of drug-eluting and bare-metal stents for primary percutaneous coronary intervention with or without abciximab in ST-segment elevation myocardial infarction: DEBATER: the Eindhoven reperfusion study. Wijnbergen I; Helmes H; Tijssen J; Brueren G; Peels K; van Dantzig JM; Van' t Veer M; Koolen JJ; Pijls NH; Michels R JACC Cardiovasc Interv; 2012 Mar; 5(3):313-22. PubMed ID: 22440498 [TBL] [Abstract][Full Text] [Related]
20. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L; N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]